Allocate has registered a good set of H1 results, albeit significantly boosted by the initial contribution from the A$10m New South Wales deal and despite weakness in Dynamic Change. Cautiously, we leave our estimates unchanged. This is a robust, cash generative business and overseas opportunities give it the potential to scale-up significantly. Consequently we feel that the current 14.3x P/E is modest.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here